Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kymera Therapeutics
KYMR
|
+$42.9M |
| 2 |
Roivant Sciences
ROIV
|
+$41.6M |
| 3 |
AbCellera Biologics
ABCL
|
+$40.9M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$20.6M |
| 5 |
IMGN
Immunogen Inc
IMGN
|
+$17.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$469M |
| 2 |
KYNB
Kyntra Bio
KYNB
|
+$39.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$15M |
| 4 |
Krystal Biotech
KRYS
|
+$13.6M |
| 5 |
Verastem
VSTM
|
+$5.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.2% |
| 2 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
| $8.57B | 49.63% |
44,554,162
-2,359,607
| -5% | -$469M |
|
2
Incyte
INCY
$25.9B
| $2.25B | 13.03% |
36,178,056
+2,656
| +0% | +$178K |
|
|
ONC
3
BeOne Medicines Ltd
ONC
$42.4B
| $2.08B | 12.04% |
11,668,897
| – | – |
|
|
4
Acadia Pharmaceuticals
ACAD
$5.08B
| $1.03B | 5.94% |
42,864,612
+926,126
| +2% | +$20.6M |
|
5
Madrigal Pharmaceuticals
MDGL
$11.9B
| $357M | 2.07% |
1,545,113
| – | – |
|
6
BioMarin Pharmaceuticals
BMRN
$12.9B
| $330M | 1.91% |
3,810,248
| – | – |
|
7
Immunocore
IMCR
$1.9B
| $151M | 0.87% |
2,520,731
| – | – |
|
8
Kodiak Sciences
KOD
$2.41B
| $119M | 0.69% |
17,310,490
| – | – |
|
|
AKRO
9
DELISTED
Akero Therapeutics
AKRO
| $111M | 0.64% |
2,368,378
| – | – |
|
10
argenx
ARGX
$65B
| $109M | 0.63% |
280,159
| – | – |
|
11
Rhythm Pharmaceuticals
RYTM
$7.57B
| $107M | 0.62% |
6,498,267
| – | – |
|
12
Replimune Group
REPL
$1.39B
| $106M | 0.62% |
4,578,280
| – | – |
|
|
13
AbCellera Biologics
ABCL
$3.67B
| $106M | 0.62% |
16,450,180
+6,000,000
| +57% | +$40.9M |
|
|
14
Kymera Therapeutics
KYMR
$9.96B
| $101M | 0.58% |
4,375,340
+1,495,515
| +52% | +$42.9M |
|
|
15
Roivant Sciences
ROIV
$26.2B
| $95M | 0.55% |
9,428,592
+4,651,162
| +97% | +$41.6M |
|
16
BioCryst Pharmaceuticals
BCRX
$2.44B
| $89.5M | 0.52% |
12,710,818
| – | – |
|
|
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
| $78.7M | 0.46% |
2,999,846
+246,344
| +9% | +$6.47M |
|
18
Entrada Therapeutics
TRDA
$295M
| $73.7M | 0.43% |
4,865,819
| – | – |
|
19
Revolution Medicines
RVMD
$44.9B
| $72M | 0.42% |
2,691,493
| – | – |
|
20
Immatics
IMTX
$1.22B
| $65.1M | 0.38% |
5,640,816
+453,735
| +9% | +$4.24M |
|
|
KDNY
21
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $55.9M | 0.32% |
1,455,202
| – | – |
|
|
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $50.9M | 0.29% |
1,409,784
| – | – |
|
|
DICE
23
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $48.1M | 0.28% |
1,035,786
| – | – |
|
24
Biomea Fusion
BMEA
$99.3M
| $46.3M | 0.27% |
2,108,949
| – | – |
|
25
Prelude Therapeutics
PRLD
$529M
| $45.6M | 0.26% |
10,123,824
| – | – |
|
Similar funds
Julian Baker's Q2 2023 Portfolio in Review
As of Q2 2023, Julian Baker held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Julian Baker's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
- Julian Baker's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
- Julian Baker added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
- Julian Baker's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
- Julian Baker fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
- Julian Baker's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
- Julian Baker opened 6 new positions and closed 5 in Q2 2023.
- Julian Baker's portfolio value fell 6% quarter-over-quarter to $17.3B.
Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.